WuXi Biologics Marks Manufacturing Triumph at Ireland’s MFG7 Facility
WuXi Biologics, a preeminent global Contract Research, Development and Manufacturing Organization (CRDMO), has recently heralded the successful execution of its inaugural manufacturing run at the MFG7 facility located in Ireland. This pivotal event signifies the company’s largest manufacturing endeavor thus far, employing four 4,000-liter single-use bioreactors to achieve an unprecedented 16,000-liter scale. The successful completion of this run not only highlights the company’s expansive capabilities but also its commitment to large-scale commercial manufacturing projects.
The company’s innovative approach has been demonstrated through this manufacturing run, revealing that the Cost of Goods (COGS) is on par with those produced by traditional stainless-steel bioreactors. CEO Dr. Chris Chen conveyed his enthusiasm regarding this progress and emphasized the significance of adopting technologies that are both environmentally and socially responsible. The company’s steadfast dedication to the development and manufacturing of life-saving treatments is aimed at providing substantial benefits to patients on a global scale.
The MFG7 facility in Ireland has garnered acclaim for its operational excellence, having been awarded the prestigious Facility of the Year Award (FOYA) in the Operations category by the International Society for Pharmaceutical Engineering (ISPE) in 2023. The facility’s commendable achievement of receiving its first Good Manufacturing Practice (GMP) certificate from the Irish Health Products Regulatory Authority (HPRA) within a mere nine months of operation is noteworthy. The site’s commitment to excellence is further evidenced by its certifications in energy management, environmental management, and occupational health and safety, which underscore its dedication to sustainability and the well-being of its employees.
With a workforce of over 12,000 skilled professionals spread across various nations, including China, the United States, Ireland, Germany and Singapore, WuXi Biologics takes pride in its comprehensive end-to-end solutions for biologics discovery, development, and manufacturing. As the year 2023 concluded, the company was actively supporting 698 integrated client projects, with 24 of these projects in the commercial manufacturing stage. Central to its business ethos is its commitment to Environmental, Social, and Governance (ESG) responsibilities, with the aim of leading the biologics CRDMO sector through sustainable practices and the utilization of clean energy.
In related developments, WuXi AppTec has seen a downturn in its share value following the introduction of a proposed US bill that seeks to limit the access of Chinese biotechnology companies to the American market. This legislative proposal, put forth by a US lawmaker, forms part of a wider array of sanctions affecting different sectors and is driven by concerns over economic, political, and human rights issues. The bill specifically targets the purported cooperation of Chinese biotech firms with the People’s Liberation Army (PLA) and the risks associated with the transfer of data to military bodies.
The landmark manufacturing run at WuXi Biologics’ MFG7 facility in Ireland is a testament to the company’s forward momentum in production capabilities and its dedication to innovation and sustainability. As the company celebrates this milestone, it remains vigilant in its navigation of the intricate web of international regulations and industry dynamics. WuXi Biologics continues to prioritize the development and manufacturing of life-saving treatments, reinforcing its position as a pivotal contributor to the global healthcare industry.
Source link
